PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24560924-4	2014	Structural analysis of oncogenic M918T and wild-type RET kinase domains reveal a cis-inhibitory mechanism involving tethering contacts between the glycine-rich loop, activation loop, and alphaC-helix.	Glycine	147-154	ret proto-oncogene	Homo sapiens	53-56	
16772843-2	2006	Screening for MEN 2B revealed a polymorphism of the RET proto-oncogene at codon 691 with a glycine to serine conversion.	Glycine	91-98	ret proto-oncogene	Homo sapiens	14-20	
16772843-2	2006	Screening for MEN 2B revealed a polymorphism of the RET proto-oncogene at codon 691 with a glycine to serine conversion.	Glycine	91-98	ret proto-oncogene	Homo sapiens	52-55	
16427628-2	2006	We showed that all RET-PTC-1 mutants in which the C in this motif (C376) was replaced with glycine, lysine, threonine or serine lost their activity in vitro.	Glycine	91-98	ret proto-oncogene	Homo sapiens	19-22	
15184865-4	2004	Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC(50): 20 nM) than the wild-type kinase.	Glycine	54-61	ret proto-oncogene	Homo sapiens	74-77	
8765374-4	1996	Ten different types of mutations were identified in the MEN 2A/FMTC families (620 Cys-->Arg, 618 Cys-->Ser, Gly, 611 Cys-->Tyr; 634 Cys-->Arg, Tyr, Trp, Phe, Ser, Gly) and all 6 MEN 2B families had a 918 Met-->Thr point mutation.	Glycine	114-117	ret proto-oncogene	Homo sapiens	56-62	
8654369-7	1996	The HSCR972 (Arg972-->Gly) mutation, mapping in the intracytoplasmic region of RET, impaired its tyrosine kinase activity, while two extracellular mutations, HSCR32 (Ser32-->Leu) and HSCR393 (Phe393-->Leu), inhibited the biological activity of RET by impairing the correct maturation of the RET protein and its transport to the cell surface.	Glycine	25-28	ret proto-oncogene	Homo sapiens	82-85